2020

Development of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves

Ahmed Al-Sabi

American University of the Middle East, Kuwait

Declan Daly

Dublin City University, Glasnevin, Dublin 9, Ireland

Myles Rooney

Dublin City University, Glasnevin, Dublin 9, Ireland

See next page for additional authors

Follow this and additional works at: <https://arrow.tudublin.ie/schfsehart>

Part of the [Food Biotechnology Commons](#), [Food Chemistry Commons](#), and the [Food Microbiology Commons](#)

Recommended Citation

A. Al-Sabi, et al. (2020). Development of a selective inhibitor for Kv1.1 channels prevalent in demyelinated nerves, *Bioorganic Chemistry*, 100 (2020) 103918. DOI:10.1016/j.bioorg.2020.103918

This Article is brought to you for free and open access by the School of Food Science and Environmental Health at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie, gerard.connolly@tudublin.ie.

Authors

Ahmed Al-Sabi, Declan Daly, Myles Rooney, Cian Hughes, Gemma K. Kinsella, Seshu Kaza, Kieran Nolan, and J. Oliver Dolly

Development of a selective inhibitor for Kv1.1 channels prevalent in demyelinated nerves

Ahmed Al-Sabi^{a,b}, Declan Daly^c, Myles Rooney^c, Cian Hughes^c, Gemma K. Kinsella^d, Seshu K. Kaza^b, Kieran Nolan^{c,*}, J. Oliver Dolly^b

^a College of Engineering and Technology, American University of the Middle East, Kuwait

^b International Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin 9, Ireland

^c School of Chemical Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland

^d School of Food Science and Environmental Health, College of Sciences and Health, Technological University Dublin, Cathal Brugha Street, Dublin 1, Ireland

ARTICLE INFO

Keywords:

Dipyromethane
Multiple sclerosis
Molecular modeling
Neuronal Kv1 channels
SAR analysis
Selective blocker design

ABSTRACT

Members of the voltage-gated K⁺ channel subfamily (Kv1), involved in regulating transmission between neurons or to muscles, are associated with human diseases and, thus, putative targets for neurotherapeutics. This applies especially to those containing Kv1.1 α subunits which become prevalent in murine demyelinated axons and appear abnormally at inter-nodes, underlying the perturbed propagation of nerve signals. To overcome this dysfunction, akin to the consequential debilitation in multiple sclerosis (MS), small inhibitors were sought that are selective for the culpable hyper-polarising K⁺ currents. Herein, we report a new semi-podand – compound **3** – that was designed based on the modelling of its interactions with the extracellular pore region in a deduced Kv1.1 channel structure. After synthesis, purification, and structural characterisation, compound **3** was found to potently (IC₅₀ = 8 μ M) and selectively block Kv1.1 and 1.6 channels. The tested compound showed no apparent effect on native Nav and Cav channels expressed in F-11 cells. Compound **3** also extensively and selectively inhibited MS-related Kv1.1 homomer but not the brain native Kv1.1- or 1.6-containing channels. These collective findings highlight the therapeutic potential of compound **3** to block currents mediated by Kv1.1 channels enriched in demyelinated central neurons.

1. Introduction

Voltage-gated K⁺ channels of the *Shaker* subfamily (Kv1) are key players in controlling neuronal excitability and synaptic transmission. Hence, their alteration by either mutation or expression levels is associated with an array of human diseases referred to as K⁺ channelopathies [1–3]. Kv1 channels are tetrameric ($\alpha_4 \beta_4$) sialoglycoproteins (Mr ~ 400 kDa) and were first purified from mammalian brain using polypeptide blockers, α dendrotoxin (α DTX) or dendrotoxin K (DTX_K) [4,5]. When expressed *in vitro*, each of the major Kv1 α subunit genes [Kv1.1–1.8] form homo-tetrameric channels exhibiting distinct biophysical and pharmacological profiles [6]. *In vivo*, neuronal Kv1 channels are located along the axons mainly as hetero-tetramers and their kinetics as well as patterns of expression are modulated by cytoplasmically-associated auxiliary β proteins [7–9]. Only a subset of the possible oligomeric combinations of Kv1 channels has been isolated from mammalian brain, including humans [10–13]. This suggests that native synthesis and/or assembly are restricted. Among all Kv1

channels expressed in neuronal membranes, the Kv1.2 is the most prevalent in forming heterotetramers with other Kv1 α subtypes (mainly with Kv1.1 and to a lesser extent with Kv1.4 and 1.6) or, in smaller proportions, as homomeric Kv1.2 channels [10,13]. Noticeably, there is preponderance in these preparations of the less abundant Kv1.1 subunit in oligomers with Kv1.2.

The voltage-dependent delayed-rectifier members of the Kv1 channel family play an important role in rapid restoration of the neuronal resting membrane potential, after depolarization. Both Kv1.1 and 1.2 channels are considered low-voltage-activated channels that open with small depolarizations at or below resting potential [14,15]. Nevertheless, the homomeric Kv1.1 channels expressed in mammalian cells activates at more negative potentials compared with its Kv1.2 counterparts [16,17]. This shift was confirmed when Kv1.1 α subunits were sequentially substituted with Kv1.2 subunits [18]. Such a difference in the voltage-dependence of activation of Kv1.1 and 1.2 would confer the rapid conduction of high-frequency action potentials exhibited between neurons [19,20]. Therefore, dysfunction or absence of

* Corresponding author.

E-mail address: Kieran.Nolan@dcu.ie (K. Nolan).

<https://doi.org/10.1016/j.bioorg.2020.103918>

Received 28 July 2019; Received in revised form 23 March 2020; Accepted 5 May 2020

Available online 06 May 2020

0045-2068/ © 2020 Published by Elsevier Inc.

Kv1.1 and 1.2 subtypes, in particular Kv1.1, is associated with various neurological disorders including epilepsy and episodic ataxia [2].

Kv1 members exposed on demyelinated axons in patients suffering from multiple sclerosis (MS) contribute to abnormal propagation of nerve signals resulting in debilitating muscle weakness [6,16]. K⁺ channels containing Kv1.1 and Kv1.2 α subunits have been found to be abnormally over-expressed outside the nodes of Ranvier in demyelinated axons of optic nerve, from a cuprizone-induced mouse model of MS [16]; importantly, the associated abnormal conductivity could be near-normalised by attenuating the Kv1.1-mediated currents with DTX_K. These findings guided our efforts to develop a small, extracellular inhibitor (compound 1) targeting such K⁺ channels to ameliorate MS-related symptoms [21]. These results indicate that up to two compounds could interact in the outer pore of Kv1 channels. Herein, analysis of structure–activity relations (SAR) led to the design of a new candidate (compound 3), a dimer of compound 1, which was shown electrophysiologically to be most potent on Kv1.1 homomeric channels like those in a rodent MS model.

2. Results and discussion

2.1. Rational design of compound 3

In our earlier work [21], [2,2'-((5,5'-(di-*p*-topyldiaryldi-(2-pyrrolyl)methane)bis(2,2'-carbonyl)bis(azanediyl)) diethaneamine.2HCl] (compound 1) (Fig. 1) was identified and characterised as a candidate to specifically block the extracellular pore of a homomeric Kv1.1 channel. It was shown to selectively inhibit this protein, recombinantly expressed in mammalian cells, with an IC₅₀ ~ 15 μ M, to induce a positive shift in the voltage-dependency of the K⁺ current activation and slow its kinetics. Also, channels containing two or more Kv1.1 α subunits proved susceptible to compound 1. Results of modelling investigations predicted a high number of localized interactions between compound 1, the selectivity filter and inner turret region residues of the channel. However, these studies highlighted an issue that compound 1 cannot take full advantage of all these important interactions with residues within the channel due to size constraints. Accordingly, the Hill slope observed for compound 1 in our earlier investigation [21] lay between 1.5 and 1.7, indicating that two molecules may be binding to the Kv1.1 channel. This observation led us to consider the possibility of covalently linking two dipyrromethane subunits together (as in the postulated compound 2, Fig. 1) at the para positions of 1, in the hope of enhancing selectivity and binding efficiency. However, initial attempts to introduce a reactive group at the para position in the phenyl groups of the

dipyrromethane scaffold in compound 1, proved unsuccessful. Further efforts failed to introduce functionality into the carboxylic acid of the dipyrromethane scaffold via condensation with various substituted benzophenone derivatives and pyrrole. Hence, a convenient synthetic route to compound 2 was not available.

An alternative new molecule, compound 3, outlined in Fig. 2, was proposed. It would possess the required two dipyrromethane moieties within the structure that are linked with a rigid isophthaloyl amide linker; the latter should reduce the degree of freedom of rotation of the dipyrromethanes relative to each other. There are a series of key structural and functional differences between the proposed compound 3 and the putative compound 2 (Figs. 1 and 2) including the replacement of one of the phenyl groups in the dipyrromethanes of compound 2 with a methyl group in compound 3. This proposed change should not significantly affect binding since the previous modelling of compound 1 with Kv1.1 demonstrated that only one of the tolyl groups made direct π - π interactions with Tyr 379, whilst the second tolyl remained on the peripheral region of the pore (see 2-D plot in [21]). Thus, removal of one of the tolyl substituents from compound 1 in theory should not disrupt its interaction with the protein. The substitution of the para methyl group in the phenyl ring in compound 2 with an amide nitrogen in compound 3 is a second change in the sub-structure of the dipyrromethane. To determine if the latter would be a viable candidate, docking with Kv1.1 was undertaken, using the homology models previously employed for compound 1.

Modelling (see Fig. 3a) revealed that the proposed isophthaloyl amide linker positions the two dipyrromethanes of compound 3 into the centre of the pore region of the channel, thereby, spatially aligning these two moieties against the corresponding residues in the protein matrix. Perhaps, the most interesting discovery from the modelling of compound 3 interacting with Kv1.1 is that, unlike our previously reported lead compound 1, compound 3 shows proximity to Tyr 379 on all the chains. Since Tyr 379 is unique to Kv1.1 and absent from Kv1.2–1.6, this intimate interaction observed with compound 3 should result in its enhanced selectivity for Kv1.1 over the other channels.

The ligand plot (Fig. 3b) indicates all the molecule-protein interactions predicted for compound 3 with Kv1.1. A major observation made from the ligand plot is the optimal hydrogen bonding (HB) between the Tyr379 and both the amide plus the terminal amine moiety of the side group of compound 3 (Fig. 3b). More detailed analysis of the modelling of compound 3 with the previously established rat Kv1.1 homology model (Fig. 3a) confirmed that the presence of a single phenyl unit in the dipyrromethanes could be sufficient for direct π - π interactions with Tyr 379 in the channel. Furthermore, there was also

Fig. 1. The structure of compound 1 and that proposed for compound 2.

Fig. 2. Schematic structure of the new semi-podand N,N'-bis isophthalamide, compound 3.

strong interaction between the terminal amine groups of compound 3 and the Asp 377 residues on two of the chains (A and B) and a potential HB between compound 3 and Tyr 375 on one of the chains (C).

2.2. Synthesis and purification of compound 3

The synthetic route for the preparation of compound 3 is outlined in Scheme 1. The first step involved the coupling of isophthaloyl chloride (4) with 4-aminoacetophenone (5), using TEA in THF at room temperature to give compound 6 in 85% yield. Condensation of compound 6 with pyrrole was initially performed using the published procedure [21] that involves $\text{BF}_3 \cdot (\text{OEt})_2$ in methanol; unfortunately, only trace quantities of compound 7 were formed. The yield of the latter was increased by condensing compound 6 in freshly distilled-pyrrole with trifluoroacetic acid (12% volume in place of $\text{BF}_3 \cdot (\text{OEt})_2$) at 70 °C over four hours; this gave 28% recovery of compound 7 after repeated chromatography. Conversion of compound 7 to 8 was achieved by treating the former with trichloroacetic anhydride (TCAA) and DMAP in CH_2Cl_2 to give the final product in 68% yield, after chromatography.

The final two steps in the synthesis of compound 3 involved treating compound 8 with *N*-Boc ethylenediamine (5 equivalents) in anhydrous CH_2Cl_2 at 0 °C to which 4 equivalents of TEA were added dropwise. After addition, the solution was allowed to heat to room temperature and stirred overnight. The resultant precipitate was filtered and washed thoroughly with both diethyl ether and CH_2Cl_2 . The collected precipitate was then suspended in anhydrous CH_2Cl_2 at 0 °C and 4 M HCl in dioxane was added dropwise at 0 °C. Once the addition was complete, the reaction was allowed to stir overnight at room temperature. The resulting precipitate formed during the reaction was isolated by filtration and washed with diethyl ether to give compound 3 in 84% yield. Its structural characterisation is detailed in the Appendix (Supplementary data)

2.3. Preferential selectivity and potent blockade by compound 3 of homomeric Kv1.1 and Kv1.6 channels but not a Kv1.6 - containing heteromer

To measure the reactivity of compound 3 with Kv1 channels, those containing the major α subunits found in the mammalian brain [6,13]

Fig. 3. A docked model of compound 3 with the pore region of Kv1.1 channel. (a) Compound 3 (in green) docked into the rat Kv1.1 homology model. Red illustrates chain A, blue relates to chain B, cyan indicates chain C and orange is chain D of the subunits. The image was generated using Pymol (The PyMOL Molecular Graphics System). (b) 2D ligand-plot of compound 3 docked onto the rat Kv1.1 homology model, illustrating the deduced interactions with numbered amino acids in the channel protein, generated by LigPlot ([22])

Scheme 1. Full schematic of the synthesis of compound 3: (i), TEA, THF, room temperature, 24hr; (ii) pyrrole, TFA, reflux, 4 hr; (iii) TCIAA, DMAP, CH₂Cl₂, room temperature; (iv) *N*-Boc ethylenediamine, TEA, CH₂Cl₂, room temperature and (v) 4 M HCl in dioxane CH₂Cl₂ room temperature.

were expressed in HEK-293 cells and their K⁺ currents recorded, using whole-cell voltage patch-clamp (Fig. 4a and b).

Representative K⁺ current traces, in the absence or presence of 10 μM compound 3, revealed a considerable inhibition of Kv1.1 (69 ± 1%, n = 6) and a lesser extent for Kv1.3 (11 ± 2%, n = 4) channels whilst being ineffective towards Kv1.2 or 1.4 homomers. Also, the Kv1.6-mediated current was reduced by 10 μM compound 3 (62 ± 11%, n = 3), close to that of Kv1.1, but not by compound 1. However, compound 3 proved unable to inhibit a transiently expressed heteromeric channel possessing one copy of Kv1.6 subunit (Kv1.4–1.2–1.2–1.6, Fig. 4a) which mimic those present in neurons [6,13,23].

The dose-dependence for the blockade of Kv1.1 by compound 3 revealed an IC₅₀ value of 8 ± 0.4 μM (n = 6); a Hill slope of 1.1 ± 0.1 indicates only unimolecular binding between the channel and compound 3. These results illustrate that a single molecule of

compound 3 is solely interacting with the tetramer channel, thus, validating our earlier hypothesis. The comparative results seen with compound 3 and the previously reported compound 1 are highly interesting; compound 3 is almost twice as potent for the Kv1.1 channel than the smaller compound 1, again in accordance with our earlier prediction [21]. Moreover, compound 3 displayed a lower level of inhibition of Kv1.3 compared to compound 1. This outcome is noteworthy because the ratio of the extent of inhibition by compound 1 under the same conditions for Kv1.1 and Kv1.3 channels was reported as 1 this has increased to ~ 4 for compound 3. Notably, the inhibitory effect of compound 3 on the Kv1.1 channel is associated with significant slowing of its activation kinetics [~16 times; 2 ± 0.1 ms before and 33 ± 2.3 ms after 10 μM compound 3, P < 0.001 n = 4, respectively] [see current traces in Fig. 4(a)]. In comparison, compound 3 showed a lower decrease in the activation kinetics of Kv1.3-mediated currents ~ 11 times [1.42 ± 0.01 ms before and 1.6 ± 0.07 ms after

Fig. 4. Selective inhibition by compound 3 of currents mediated by various Kv1 channels, expressed in HEK-293 cells. (a) Representative current traces from Kv1.1, 1.2 and Kv1.6 homomeric and Kv1.4–1.2–1.2–1.6 channels in the absence (black) and presence of 10 μM compound 3, generated by a step voltage from the holding potential to 20 mV. (b) Summary of the dissimilar pharmacological profiles of five Kv1 channels shown for 10 μM compound 3. Notably, Kv1.1 and Kv1.6 were inhibited significantly, with a minimal extent for Kv1.3, whereas Kv1.2 and 1.4 proved insensitive. (c) Representative dose–response curve, obtained from Qpatch recording, for Kv1.1 inhibition by compound 3. Some of the error bars fall within the data points. The IC_{50} values are given in the text. (d) The histograms summarise the selectivity of compound 3 (10 μM ; filled bars) over compound 1 in inhibiting each K^+ current.

Fig. 5. Compound 3 does not inhibit Nav or Cav channels in F-11 cells. (a) Native Nav channels (black traces) were insensitive to 10 μM compound 1 or 3 (grey traces) at -30 mV potentials. The bar-diagram summarises the lack of inhibition of Nav currents by either compound ($n = 4$ for all). Experiments were conducted with 100 μM Cd^{2+} and internal 125 mM Cs^+ to block native Cav and Kv channels, respectively. (b) Native Cav channels (black traces) recorded in the presence of 1 μM TTX to block Na_v and Cs^+ for inhibiting K^+ channels, respectively, are shown for compound 1 or 3 (grey) at -30 mV (for Nav channels) and -40 mV (for Cav channels) potentials. The adjacent diagram reveals a significant $\sim 33\%$ reduction of Ca^{2+} currents by compound 1 (grey) compared to that of control currents (clear; $P < 0.001$, $n = 4$ for all), and the absence of any inhibition of Cav currents by compound 3 (black).

10 μM compound **3**, $P = 0.0646$, $n = 3$, respectively]. These data reveal the notably similar inhibition pattern, particularly the slowing of activation kinetics by compounds **3** and **1** [21] with more prominent inhibition exerted by compound **3**.

Next, concatenated Kv1.1 and/or Kv1.2 channels were evaluated for inhibition by compound **3** of Kv1 channels (Fig. 4d) resembling those in demyelinated neurons [16] in comparison to compound **1**. Only Kv1.1 homo-tetramers and some heteromeric Kv1.1-enriched channels (those with 3 copies of Kv1.1) are inhibited regardless of their arrangement in the tetramer. Notice a significant difference between the blockade by compound **3** of homo-tetrameric Kv1.1 channel [$66 \pm 1\%$ ($n = 3$)] compared to Kv(1.1)₃-1.2 channels [Kv1.1-1.1-1.1-1.2: $8 \pm 1\%$ ($n = 3$) and Kv1.1-1.2-1.1-1.1: $8 \pm 0.5\%$ ($n = 3$); $p < 0.0001$, each]. This compound lacks significant reactivity towards channels with two, one or no copies of Kv1.1 subunit in the tested tetramers [Kv1.1-1.1-1.2-1.2: $3 \pm 0.4\%$ ($n = 3$), Kv1.1-1.2-1.2-1.2: $3 \pm 0.1\%$ ($n = 3$) and Kv1.2-1.2-1.2-1.2: $2 \pm 0.1\%$ ($n = 3$), respectively]. On the other hand, compound **1** equally inhibits tetrameric channels containing two Kv1.1 subunit [Kv1.1-1.1-1.2-1.2: $15 \pm 2\%$ ($n = 5$)] or three copies of Kv1.1 subunits irrespective of their positions [Kv1.1-1.1-1.1-1.2: $15 \pm 3\%$ ($n = 4$) and Kv1.1-1.2-1.1-1.1: $17 \pm 3\%$ ($n = 7$)]. Compound **1** showed no apparent inhibition of Kv1.1-1.2-1.2-1.2 channel: $4 \pm 1\%$ ($n = 4$) or tetrameric Kv1.2 channel: $2 \pm 0.03\%$ ($n = 4$). These data reveal that compound **3** is a more selective blocker of homotetrameric Kv1.1 channel compared to its precursor. To evaluate the reactivity of compound **3** (in comparison to **1**) with Nav and Cav channels, DRG hybridoma cell line (F-11) was used because it is known to be enriched with such channels; these include subtypes concerned with pain transduction: Nav1.6, Nav1.7 and Nav1.8 and most Cav channels (mainly Cav 3.3, 3.2, 2.2, 2.1 and 1.2) [24]. Neither of the candidates inhibited native TTX-sensitive Nav currents (such as Nav 1.6 or Nav 1.7) in F11 cells (Fig. 5a). Only compound **1** showed a partial block of the Cav channels (Fig. 5b).

Collectively, these findings further emphasise the selective nature and specificity of compound **3** in blocking Kv1 channels without affecting native neuronal Nav and Cav channels.

As Kv1.1 homotetramers have been found only to be expressed in demyelinated neurons, these channels are considered a promising target for small extracellular blockers to normalize reduced excitability, hence, potentially ameliorate symptoms in MS. In fact, the abnormal conductivity in demyelinated axons were nearly normalized by attenuating the Kv1.1-mediated currents with the available selective blocker (DTX_K) of Kv1.1 homotetramers [16]. Unfortunately, the avid DTX_K peptide toxin cannot be considered as a potential neurotherapeutic. Towards this end, we were encouraged to develop synthetic inhibitors selective for such MS-associated channels. A rational design using SAR analysis led initially to the formation and characterization of compound **1**, that showed selectivity for Kv1.1 channels [21]. This encouraged us to suspect that linking two copies of compound **1**, in a para position, could enhance selectivity and binding efficiency to regions at the selectivity filter to residues in the inner turret region of the Kv1.1 channel. In the present study, a dimeric form of compound **1**, with a covalent linker inserted created the formation of compound **3**.

As predicted, compound **3** was shown to have double the potency towards Kv1.1 with a Hill slope ~ 1 , confirming a single molecule binding to a Kv1.1 channel. It is not surprising that compound **3** inhibits Kv1.1 and 1.6 channels since both share similarity in key interacting residues at the inner turret region (Tyr 379 in Kv1.1 and Tyr 429 in Kv1.6). As Kv1.6-enriched channels are not found in native or demyelinated neuronal preparations [10–13,16], such cross-reactivity seen with compound **3** should not prove to be an issue. Also, compound **3** has no apparent effect on native Nav and Cav channels expressed in F-11 cells, unlike compound **1** which exhibited some inhibition of Cav current. This is an advantage of compound **3** in being specific for Kv1.1-containing channels and not cross-react with other native ion channels. On the other hand, the dual effect of both compounds, by inhibiting K⁺

currents and slowing the activation kinetics of blocked channels found to be advantageous in overcoming the hypo-excitability and accelerated the activation kinetics seen in demyelinated optic axons [16]. Interestingly, compound **3**, unlike its precursor, showed to be a more selective blocker of homo-tetrameric Kv1.1 than Kv1.1-containing channels (with 1–3 Kv1.1 copies). The therapeutic usage of 4-aminopyridine (4-AP) is limited by being non-selective between Kv1 channel types and causing seizures [25]. Unlike 4-AP, compound **3** is exclusively reactive with Kv1.1 and devoid of the effect on the most prevalent subtype, Kv1.2; this is an extra advantageous feature especially being selective for those channels only associated with demyelinated neurons, and not natively-expressed varieties in nearby healthy neurons.

3. Conclusions

This work demonstrated that the dimeric compound **3** is a preferential inhibitor of Kv1.1 channels relative to compound **1**. Its design was based on *in silico* and electrophysiological investigations that established two copies of compound **1** are needed to block the extracellular pore region of Kv1.1 channel. This hypothesis was validated by the observation that compound **3** displays a more potent and selective blockade of Kv1.1-enriched channels, found in demyelinated neurons (see below). Such inhibition is also associated with slowing the activation kinetics of the channels. Although compound **3** displays twice the inhibitory efficacy of compound **1** on Kv1.1, it also inhibits Kv1.6. The latter seems to result from a key interaction with a Tyr in the inner turret region of Kv1.6, as this same residue also exists in the inner turret of Kv1.1. Fortunately, homomeric Kv1.6 has not been detectable in brain synaptic membrane [8]. Furthermore, compound **3** offers an additional advantage of interacting with heteromeric channels possessing three copies of Kv1.1 or Kv1.1 homomers; importantly, these are the channels shown to be expressed on demyelinated neurons and responsible for their hypo-excitability [16,21]. Moreover, compound **3** does not affect Nav or Cav channels, at least at the 10 μM tested. These collective findings highlight the therapeutic potential of compound **3** to block currents mediated by Kv1.1 channels enriched in demyelinated central neurons.

4. Experimental section

4.1. Chemistry

4.1.1. N1, N3-bis(4-acetylphenyl)-1,3-benzenedicarboxamide compound **6**

To a 250 mL round bottom flask, 4.3 g (32.5 mmol) of 4-aminoacetophenone (**5**) was added and dissolved in 45 mL of anhydrous THF. After adding anhydrous TEA (2.5 mL), the reaction mixture was chilled to 0 °C and stirred; isophthaloyl chloride (**4**) (3.0 g 14.8 mmol) was dissolved in 30 mL of anhydrous THF and added dropwise to the stirred solution. The reaction was stirred for 4 h before filtering the precipitate. After washing the precipitate with 5x50 mL H₂O and 5x50 mL of CH₂Cl₂, it was dried to give **6** as a white solid in 85% yield (5.02 g).

¹H NMR (400 MHz) δ (DMSO- *d*₆) 10.7 (2H, s, NH) 8.5 (1H, s, CH) 8.1 (2H, m, CH) 7.9 (8H, dd, *p*-Phenyl-H) 7.7 (1H, t, CH) 2.4 (6H, s, CH₃) ¹³C NMR (100 MHz, DMSO- *d*₆) 196.6, 165.4, 143.4, 134.8, 132.1, 131.1, 129.3, 128.8, 127.2, 119.5, 26.5.

4.1.2. Compound **7**

To a 100 mL round bottom flask, 1 g (2.49 mmol) of **6** was added, followed by 15 mL (216 mmol) of freshly-distilled pyrrole. TFA (2 mL) was added dropwise and stirred at 70 °C for 4 h. The reaction was quenched with 5 mL of TEA and stirred at room temperature for 20 mins. Unreacted pyrrole was removed under high vacuum at 50 °C to leave a black tar-like oil. The crude reaction mixture was purified twice by silica gel chromatography, eluted with hexane: ethyl acetate (3:2); after removal of the solvent under reduced pressure, compound **7** was obtained as a beige solid in 28% yield (450 mg).

^1H NMR (400 MHz) δ (DMSO- d_6) 10.4 (6H, m, NH pyrrole + NH amide) 8.5 (1H, s, CH) 8.1 (2H, m, CH) 7.7 (5H, d, phenyl-H + CH) 7.0 (4H, d, phenyl-H) 6.7 (4H, m, pyrrole-H) 5.9 (4H, s, pyrrole-H) 5.6 (4H, m, pyrrole-H) 2.0 (6H, s, CH_3) ^{13}C NMR (100 MHz, DMSO- d_6) 165.8, 145.2, 138.7, 137.9, 136.1, 131.5, 129.5, 128.3, 127.9, 120.4, 118.1, 107.2, 106.8, 44.8, 28.9

4.1.3. Compound 8

To a 50 mL round bottom flask, 200 mg (0.316 mmol) of compound 7 was added with 18 mg (0.158 mmol) of DMAP. These were suspended in 10 mL anhydrous CH_2Cl_2 , chilled to 0 °C and placed under an argon atmosphere. To this mixture was added dropwise 0.288 mL (1.58 mmol) of trichloroacetic anhydride and the reaction mixture allowed to stir at room temperature for 2 h. The reaction was then stopped by the addition of aqueous NaHCO_3 and the organic layer washed with brine (2x10 mL); the organic layer was dried over MgSO_4 and the solvent removed under reduced pressure. The resulting crude product was then purified by silica gel column chromatography, eluting with ethyl acetate and hexane (1:3) to give 8 as a white solid in 68% yield (0.2614 g).

^1H NMR (400 MHz) δ (DMSO- d_6) 12.2 (4H, s, NH-pyrrole) 10.5 (2H, s, NH-amide) 8.5 (1H, s, CH) 8.1 (2H, m, CH) 7.8–7.7 (5H, d, phenyl-H + CH) 7.3 (4H, m, pyrrole-H) 7.0 (4H, d, phenyl-H) 6.1 (4H, m, pyrrole-H) 2.1 (6H, s, CH_3) ^{13}C NMR (100 MHz, DMSO- d_6) 171.8, 165.0, 147.8, 141.0, 137.7, 135.0, 130.7, 128.6, 127.3, 127.0, 122.3, 121.2, 120.4, 111.3, 95.3, 45.2, 27.5.

4.1.4. Compound 3

To a 25 mL round bottom flask was added 150 mg (0.125 mmol) of 8 and 5 mL of anhydrous CH_2Cl_2 ; the mixture was placed under an argon atmosphere. To this was added dropwise 0.094 mL (0.592 mmol) of *N*-Boc ethylenediamine and the reaction mixture allowed to stir for 10 mins. Anhydrous TEA (0.082 mL, 0.592 mmol) was then added and the mixture stirred for 24 h at room temperature under an argon atmosphere. The resulting precipitate was vacuum filtered using a glass frit and washed thoroughly with CH_2Cl_2 to give a white/beige solid (144 mg). This precipitate (100 mg) was placed in a 25 mL round bottom flask, followed by the addition of 5 mL of anhydrous CH_2Cl_2 ; the mixture was then placed under an argon atmosphere and chilled to 0 °C. After the addition of 1 mL of 4 M HCl in dioxane was complete (addition is done at 0 °C), the reaction was left stirring for 24 h at room temperature. The precipitate that formed was vacuum filtered and washed with CH_2Cl_2 to give compound 3 in 84% yield.

^1H NMR (400 MHz) δ (DMSO- d_6) 11.2 (4H, s, NH-pyrrole) 10.6 (2H, s, NH-amide) 8.7 (1H, s, CH) 8.3 (4H, t, NH-amide) 8.1 (2H, m, CH) 8.0 (12H, s, NH_3^+) 7.7 (5H, d, phenyl-H + CH) 6.9 (4H, d, phenyl-H) 6.7 (4H, m, pyrrole-H) 5.9 (4H, m, pyrrole-H) 3.3 (8H, m, CH_2) 2.9 (8H, m, CH_2) 2.0 (6H, s, CH_3)

HR-MALDI MS: Calculated ($\text{M} - 4\text{HCl}$: 976.4820) Observed ($\text{M} + 1 - 4\text{HCl}$: 977.4899)

4.2. Molecular biology

4.2.1. DNA constructs

cDNAs for rat Kv1.1, 1.2, 1.3, 1.4 and 1.6 were kindly provided by Professor Olaf Pongs (Institute for Neural Signal Transduction, University of Hamburg, Germany). Concatenation of four α Kv1.1 and/or Kv1.2, Kv1.4 with Kv1.2 and Kv1.6 subunits as a single ORF was accomplished using an inter-subunit linker derived from the untranslated regions (UTRs) of the *Xenopus* β -globin gene (GenBank® accession number J00978) [26,27] as reported previously [21]

4.2.2. Expression of Kv1 channels in HEK293 cells

Kv1.1, 1.2, 1.3, 1.4, and 1.6, Kv1.1-homotetramers, Kv1.2-homotetramers, Kv1.1–1.2–1.1–1.1, Kv1.1–1.1–1.1–1.2, Kv1.1–1.1–1.2–1.2, and Kv1.1–1.2–1.2–1.2 channels were stably expressed in HEK-293

cells (American Type Culture Collection) [21]. Kv1.4–1.2–1.2–1.6 channel [23], was transiently transfected into HEK-293 cells using Trans-293® transfection reagent (Mirus Bio LLC, Madison, WI, USA).

4.2.3. Electrophysiological recordings and data analysis

Whole-cell voltage clamp was performed as previously outlined [18,28], except where specified. In the conventional patch clamp system [EPC10 amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany)], the recording pipette was filled with an internal solution that contained (in mM): 95 KF, 30 KCl, 1 CaCl_2 , 1 MgCl_2 , 11 EGTA, 10 HEPES, 2 K_2ATP (pH 7.2 with KOH), having fire-polished tips of resistances between 2 and 5 M Ω . Composition of the external (bath) medium (in mM) was: 135 NaCl, 5 KCl, 2 CaCl_2 , 2 MgCl_2 , and 5 Hepes, and 10 sucrose (pH 7.4 with NaOH). A correction was made for liquid junction potential (+7 mV). Leakage and capacitive currents were subtracted on-line using the P/4 subtraction protocol. Currents were filtered at 1 kHz and sampled at 10 kHz. Only cells with a K^+ current (I_K) of $> 1\text{ nA}$ were chosen for experimentation, to avoid interference from endogenous outward currents ($< 200\text{ pA}$ at +20 mV potential), and having series resistances $< 10\text{ M}\Omega$ throughout the experiments. Whole-cell currents were measured at a holding potential of -90 mV , and then depolarized to +20 mV for 300 ms or stepped from the holding potential in +10 mV increments to +80 mV. Currents from the Kv channels tested were calculated from averaged steady-state currents after 200 ms of activation. For Kv1.4, currents were determined from the averaged peak after activation.

Automated whole-cell voltage clamp system (QPatch 16, Sophion Bioscience, Ballerup, Denmark) was performed as previously outlined [18], using the same internal and external solutions as in the conventional system. Inhibition by compounds was determined by the Hill equation fitting 9 concentrations. The results obtained with the QPatch 16 were confirmed by the conventional electrophysiological recordings. Compounds for testing were dissolved in the extracellular solution as stock solutions of 10 mM and stored at $-20\text{ }^\circ\text{C}$. These were diluted in the extracellular solution in amber tubes to desired concentrations before being applied directly to the recording chamber (0.5 mL) at a flow rate of $\sim 2\text{ mL/min}$.

Electrophysiological results were re-plotted and fitted using Igor pro 6 (WaveMetrics, Lake Oswego, OR, USA). Data are reported as mean $\pm$ S.E.M.; n values refer to a number of individual cells tested. Statistical significance was evaluated by an unpaired two-tailed Student's *t*-test, using data obtained from at least three independent experiments. *P* values < 0.01 were considered significant.

4.2.4. Screening of endogenous voltage-activated Na^+ (Nav) and Ca^{2+} (Cav) channels

F-11 cells (DRG neuroblastoma mouse cell line, N18TG2, ECACC) were cultured using Dulbecco's modified Eagle's medium supplemented with 10% deactivated foetal bovine serum and 1% penicillin-streptomycin solution (Sigma-Aldrich) Wicklow, Ireland. Native Nav channels (tetrodotoxin-sensitive [24]), were pharmacologically isolated by exposing the cells to 100 μM Cd^{2+} , whereas isolation of inward Ca^{2+} current was achieved by including 1 μM TTX in the extracellular recording solution. Native K^+ currents were blocked by replacing K^+ with equal molarity of Cs^+ in the internal recording solution (125 mM $[\text{Cs}]_i$). Inward Na^+ and Ca^{2+} currents were calculated from the average current peaks at -30 mV and -40 mV , respectively.

4.3. Computation

A homology model for the rat Kv1.1 channel was developed and validated, as previously described [21,29]. For ligands, Accelrys Discovery Studio 3.5 (Release 3.5, Accelrys Inc., San Diego, USA), was utilised to enumerate tautomers, stereoisomers, and conformations.

4.3.1. Molecular docking.

AutoDock 4 was used for molecular docking with flexible ligands [30,31]. Flexible residues in the protein were defined as residues 375–381 in each monomer [29]. A cubic grid of $140 \text{ \AA} \times 140 \text{ \AA} \times 140 \text{ \AA}$ around the ion pore was constructed using the Autogrid program, with a grid point step of $0.375 \text{ \AA}$. Default parameters were implemented in Autodock4 with 50 docking runs, while `ga_num_evals` was set to 25,000,000 and `ga_num_generations` fixed at 27,000. The AutoDock Tools program [32] was employed for the generation of input files. The conformations showing lower free energy of binding for each ligand were further analyzed.

Acknowledgments

This work was funded by a Principle Investigator grant from Science Foundation Ireland (to J.O.D.), a DCU President scholarship (for S.K.), an Irish Research Council Scholarship (for D.D.) and the Programme for Research in Third Level Institutions (PRTL) Cycle 4. The PRTL is co-funded through the European Regional Development Fund (ERDF), part of the European Union Structural Funds Programme 2007–2013.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bioorg.2020.103918>.

References

- [1] M.C. D'Adamo, L. Catacuzzeno, G. Di Giovanni, F. Franciolini, M. Pessia, K(+) channelopathy: progress in the neurobiology of potassium channels and epilepsy, *Front Cell Neurosci* 7 (2013) 134.
- [2] F.M. Ashcroft, Ion channels and disease: Channelopathies, Academic Press, San Diego, 2000.
- [3] D.M. Kullmann, The neuronal channelopathies, *Brain* 125 (Pt 6) (2002) 1177–1195.
- [4] D.N. Parcej, V.E. Scott, J.O. Dolly, Oligomeric properties of alpha-dendrotoxin-sensitive potassium ion channels purified from bovine brain, *Biochemistry* 31 (45) (1992) 11084–11088.
- [5] F.C. Wang, D.N. Parcej, J.O. Dolly, alpha subunit compositions of Kv1.1-containing K+ channel subtypes fractionated from rat brain using dendrotoxins, *Eur J Biochem* 263 (1) (1999) 230–237.
- [6] S.V. Ovsepian, M. LeBerre, V. Steuber, V.B. O'Leary, C. Leibold, J. Oliver Dolly, Distinctive role of KV1.1 subunit in the biology and functions of low threshold K(+) channels with implications for neurological disease, *Pharmacol Ther* 159 (2016) 93–101.
- [7] J. Rettig, S.H. Heinemann, F. Wunder, C. Lorra, D.N. Parcej, J.O. Dolly, O. Pongs, Inactivation properties of voltage-gated K+ channels altered by presence of beta-subunit, *Nature* 369 (6478) (1994) 289–294.
- [8] V.E. Scott, Z.M. Muniz, S. Sewing, R. Lichtinghagen, D.N. Parcej, O. Pongs, J.O. Dolly, Antibodies specific for distinct Kv subunits unveil a heterooligomeric basis for subtypes of alpha-dendrotoxin-sensitive K+ channels in bovine brain, *Biochemistry* 33 (7) (1994) 1617–1623.
- [9] V.E. Scott, J. Rettig, D.N. Parcej, J.N. Keen, J.B. Findlay, O. Pongs, J.O. Dolly, Primary structure of a beta subunit of alpha-dendrotoxin-sensitive K+ channels from bovine brain, *Proc Natl Acad Sci U S A* 91 (5) (1994) 1637–1641.
- [10] S.K. Coleman, J. Newcombe, J. Pryke, J.O. Dolly, Subunit composition of Kv1 channels in human CNS, *J Neurochem* 73 (2) (1999) 849–858.
- [11] R.O. Koch, S.G. Wanner, A. Koschak, M. Hanner, C. Schwarzer, G.J. Kaczorowski, R.S. Slaughter, M.L. Garcia, H.G. Knaus, Complex subunit assembly of neuronal voltage-gated K+ channels, Basis for high-affinity toxin interactions and pharmacology, *J Biol Chem* 272 (44) (1997) 27577–27581.
- [12] A. Koschak, R.M. Bugianesi, J. Mitterdorfer, G.J. Kaczorowski, M.L. Garcia, H.G. Knaus, Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from *Centruroides limbatus* venom, *J Biol Chem* 273 (5) (1998) 2639–2644.
- [13] O.G. Shamotienko, D.N. Parcej, J.O. Dolly, Subunit combinations defined for K+ channel Kv1 subtypes in synaptic membranes from bovine brain, *Biochemistry* 36 (27) (1997) 8195–8201.
- [14] H.M. Brew, J.L. Hallows, B.L. Tempel, Hyperexcitability and reduced low threshold potassium currents in auditory neurons of mice lacking the channel subunit Kv1.1, *J Physiol* 548 (Pt 1) (2003) 1–20.
- [15] H.M. Brew, J.X. Gittelman, R.S. Silverstein, T.D. Hanks, V.P. Demas, L.C. Robinson, C.A. Robbins, J. McKee-Johnson, S.Y. Chiu, A. Messing, B.L. Tempel, Seizures and reduced life span in mice lacking the potassium channel subunit Kv1.2, but hypoeccitability and enlarged Kv1 currents in auditory neurons, *J Neurophysiol* 98 (3) (2007) 1501–1525.
- [16] B. Bagchi, A. Al-Sabi, S. Kaza, D. Scholz, V.B. O'Leary, J.O. Dolly, S.V. Ovsepian, Disruption of myelin leads to ectopic expression of K(V)1.1 channels with abnormal conductivity of optic nerve axons in a cuprizone-induced model of demyelination, *PLoS One* 9(2) (2014) e87736.
- [17] S. Grissmer, A.N. Nguyen, J. Aiyyar, D.C. Hanson, R.J. Mather, G.A. Gutman, M.J. Karmilowicz, D.D. Auperin, K.G. Chandy, Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines, *Mol Pharmacol* 45(6) (1994) 1227–34.
- [18] A. Al-Sabi, S.K. Kaza, J.O. Dolly, J. Wang, Pharmacological characteristics of Kv1.1- and Kv1.2-containing channels are influenced by the stoichiometry and positioning of their alpha subunits, *Biochem J* 454 (1) (2013) 101–108.
- [19] H. Wang, M.L. Allen, J.J. Grigg, J.L. Noebels, B.L. Tempel, Hypomyelination alters K+ channel expression in mouse mutants shiverer and Trembler, *Neuron* 15 (6) (1995) 1337–1347.
- [20] H. Wang, D.D. Kunkel, T.M. Martin, P.A. Schwartzkroin, B.L. Tempel, Heteromultimeric K+ channels in terminal and juxtaparanodal regions of neurons, *Nature* 365 (6441) (1993) 75–79.
- [21] A. Al-Sabi, D. Daly, P. Hoefer, G.K. Kinsella, C. Metais, M. Pickering, C. Herron, S.K. Kaza, K. Nolan, J.O. Dolly, A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction, *J Med Chem* 60 (6) (2017) 2245–2256.
- [22] R.A. Laskowski, M.B. Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, *J Chem Inf Model* 51 (10) (2011) 2778–2786.
- [23] A. Al-Sabi, S. Kaza, M. Le Berre, L. O'Hara, M. Bodeker, J. Wang, J.O. Dolly, Position-dependent attenuation by Kv1.6 of N-type inactivation of Kv1.4-containing channels, *Biochem J* 438 (2) (2011) 389–396.
- [24] K. Yin, G.J. Baillie, I. Vetter, Neuronal cell lines as model dorsal root ganglion neurons: A transcriptomic comparison, *Mol Pain* 12 (2016).
- [25] H.B. Jensen, M. Ravnborg, U. Dalgas, E. Stenager, 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review, *Ther Adv Neurol Disord* 7 (2) (2014) 97–113.
- [26] S. Akhtar, O. Shamotienko, M. Papakosta, F. Ali, J.O. Dolly, Characteristics of brain Kv1 channels tailored to mimic native counterparts by tandem linkage of alpha subunits: implications for K+ channelopathies, *J Biol Chem* 277 (19) (2002) 16376–16382.
- [27] M.V. Sokolov, O. Shamotienko, S.N. Dhochartaigh, J.T. Sack, J.O. Dolly, Concatemers of brain Kv1 channel alpha subunits that give similar K+ currents yield pharmacologically distinguishable heteromers, *Neuropharmacology* 53 (2) (2007) 272–282.
- [28] A. Al-Sabi, O. Shamotienko, S.N. Dhochartaigh, N. Muniyappa, M. Le Berre, H. Shaban, J. Wang, J.T. Sack, J.O. Dolly, Arrangement of Kv1 alpha subunits dictates sensitivity to tetraethylammonium, *J Gen Physiol* 136 (3) (2010) 273–282.
- [29] D. Daly, A. Al-Sabi, G.K. Kinsella, K. Nolan, J.O. Dolly, Porphyrin derivatives as potent and selective blockers of neuronal Kv1 channels, *Chem Commun (Camb)* 51 (6) (2015) 1066–1069.
- [30] R. Huey, G.M. Morris, A.J. Olson, D.S. Goodsell, A semiempirical free energy force field with charge-based desolvation, *J Comput Chem* 28 (6) (2007) 1145–1152.
- [31] G.M. Morris, D.S. Goodsell, R. Huey, A.J. Olson, Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4, *J Comput Aided Mol Des* 10 (4) (1996) 293–304.
- [32] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, *J Comput Chem* 30 (16) (2009) 2785–2791.